It is currently Tue Dec 12, 2017 2:36 am

News News of Tcelna (Tovaxin)

Site map of Tcelna (Tovaxin) » Forum : Tcelna (Tovaxin)

A board to discuss Tcelna as a treatment for Multiple Sclerosis

Goodbye Opexa: Acer and Opexa Close Merger

Goodbye Opexa...

Acer Therapeutics and Opexa Therapeutics Close Merger and Financing
Sep 19, 2017

https://acertx.com/acertherapeuticsando ... financing/

  • Merger to create a pre-NDA-stage, Nasdaq-listed, pharmaceutical company focused on the development and commercialization of therapies for serious rare diseases with critical unmet
    medical need
  • Combined company, renamed Acer Therapeutics Inc., to commence trading on Nasdaq under the
    symbol “ACER” on September 21
  • Concurrent financing of $15.7 million from Acer investor syndicate
  • ...
Read more : Goodbye Opexa: Acer and Opexa Close Merger | Views : 723 | Replies : 1


Opexa Therapeutics targets neuromyelitis optica

Opexa Therapeutics targets neuromyelitis optica via OPX-12

http://www.opexatherapeutics.com/OPX-21 ... fault.aspx

OPX-212 is an autologous T-cell immunotherapy being developed for the treatment of Neuromyelitis Optica (NMO). NMO is an autoimmune disorder in which immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord leading to demyelination and loss of axons. There are currently no FDA-approved therapies for NMO.

OPX-212 is specifically tailored ...
Read more : Opexa Therapeutics targets neuromyelitis optica | Views : 1953 | Replies : 0


Phase IIb SPMS Trial Results

Opexa's stock price crashed on Oct. 28th. It's now at 67 cents/share.

http://money.cnn.com/quote/quote.html?symb=OPXA
Read more : Phase IIb SPMS Trial Results | Views : 1191 | Replies : 3


Anyone else out there with similar experience with Tovaxin?

Help! Anyone else out there with similar experience with Tovaxin? This is a long post but worth considering a new possibility on the road to full recovery.

I do not have MS, but my immediate family member was in Tovaxin study completed by Opexa Therapeutics. I cannot begin to describe how positive the results were for her. Unfortunately, as many of you might already know, once you have completed one of the trials you are ...
Read more : Anyone else out there with similar experience with Tovaxin? | Views : 2442 | Replies : 5


Opexa Presentation at Vatican

Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons:
The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican.

Here is the link of the video:
http://www.opexatherapeutics.com/news-a ... fault.aspx
Read more : Opexa Presentation at Vatican | Views : 1395 | Replies : 0


SPMS Trial?

Does anyone know what's going on with Opexa's phase II trial for SPMS? Their stock has seen some recent activity, but it's been under $1/share since November 1, 2014. They're required to be over $1 in order to stay listed on the NASDAQ. Unless they can pull the proverbial rabbit out of a hat, I predict yet another reverse split is on the way.
Read more : SPMS Trial? | Views : 2576 | Replies : 2


‘Personalised’ treatment results due next year

After the Phase 2b clinical trial achieved full enrolment with 190 secondary progress multiple sclerosis (SPMS) patients, Texas-based Opexa Therapeutics is now awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016..... Read More - http://www.ms-uk.org/tcelna
Read more : ‘Personalised’ treatment results due next year | Views : 1871 | Replies : 0


Opexa news: NMO

It looks like Opexa is working on a treatment for Neuromyelitis Optica.

http://www.opexatherapeutics.com/OPX-21 ... fault.aspx
Read more : Opexa news: NMO | Views : 2404 | Replies : 0


Merck Serono Enter into Option and License for Tcelna

Opexa Therapeutics Inc. (OPXA) granted an exclusive license option to Germany-based Merck KGaA's (MKGAY, MRK.XE) biopharmaceutical division for the development and commercialization of Opexa's lead product candidate, Tcelna, for multiple sclerosis in a deal potentially valued at $225 million

They must see something of value?!?!

http://online.wsj.com/article/BT-CO-201 ... 08051.html
Read more : Merck Serono Enter into Option and License for Tcelna | Views : 2826 | Replies : 2


Opexa reverse split

As I had predicted almost a year ago, on December 14th Opexa executed another reverse split. This time it was 1:4. Since then, their stock has fallen an additional 35.2% in value. This does not seem to put them in a good position for their ongoing trial of Tovaxin (Tcelna) with SPMS.

http://www.opexatherapeutics.com/121412 ... cle=121412

NHE
Read more : Opexa reverse split | Views : 2814 | Replies : 0


 

Login  •  Register


Statistics

Total posts 241191 • Total topics 26394 • Total members 17566


Contact us | Terms of Service